A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

October 5, 2024

Study Completion Date

November 20, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

HSK7653 10 mg

HSK7653 10 mg Q2W

DRUG

Daily DPP-4 inhibitor

Trial Locations (1)

Chu Hsien-I Memorial Hospital, Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06703268 - A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients | Biotech Hunter | Biotech Hunter